Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-37942
Titel: | Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma : A Series of 12 Patients |
VerfasserIn: | DeTemple, Viola K. Hassel, Jessica C. Sachse, Michael M. Grimmelmann, Imke Leiter, Ulrike Gebhardt, Christoffer Eckardt, Julia Pföhler, Claudia Angela, Yenny Hübbe, Hanna Gutzmer, Ralf |
Sprache: | Englisch |
Titel: | Cancers |
Bandnummer: | 14 |
Heft: | 21 |
Verlag/Plattform: | MDPI |
Erscheinungsjahr: | 2022 |
Freie Schlagwörter: | advanced basal cell carcinoma hedgehog inhibitor reinduction sequential treatment checkpoint inhibition |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure. Retrospective data analysis was performed with 12 patients with aBCC (locally advanced (n = 8)/metastatic (n = 4)). These patients (male:female 6:6, median age 68 years) initially received HHIs, leading to complete/partial response (66%) or stable disease (33%). Median treatment duration was 20.8 (2–64.5) months until discontinuation due to progression (n = 8), adverse events (n = 3), or patient request (n = 1). Subsequent PD1 inhibition (pembrolizumab 42%, cemiplimab 58%) yielded a partial response (8%), stable disease (33%), or progression (59%). Median treatment duration was 4.1 (0.8–16.3) months until discontinuation due to progression (n = 9), adverse events (n = 1), patient request (n = 1), or missing drug approval (n = 1). HHI reinduction resulted in complete/partial response (33%), stable disease (50%), or progression (17%). Median treatment duration was 3.6 (1–29) months. Response duration in the four responding patients was 2–29+ months. Thus, a subgroup of patients with aBCC responded to reinduction of HHI following PD1i failure. Therefore, this sequential treatment represents a feasible treatment option. |
DOI der Erstveröffentlichung: | 10.3390/cancers14215469 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-379428 hdl:20.500.11880/34297 http://dx.doi.org/10.22028/D291-37942 |
ISSN: | 2072-6694 |
Datum des Eintrags: | 11-Nov-2022 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Dermatologie |
Professur: | M - Keiner Professur zugeordnet |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
cancers-14-05469-v2.pdf | 1,06 MB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons